Last reviewed · How we verify
Placebo (WO3988)
Placebo produces therapeutic effects through patient expectation and the psychobiological response to treatment.
At a glance
| Generic name | Placebo (WO3988) |
|---|---|
| Sponsor | Dr. August Wolff GmbH & Co. KG Arzneimittel |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo works via the placebo effect, wherein a patient's belief in receiving treatment activates neurobiological pathways that can reduce symptoms and improve outcomes, independent of pharmacological activity. This involves activation of endogenous pain-relief systems, expectancy-driven neural responses, and conditioning mechanisms. The effect is particularly pronounced in conditions with subjective symptom components such as pain, nausea, and fatigue.
Approved indications
Common side effects
Key clinical trials
- Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis. (PHASE3)
- Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (WO3988) CI brief — competitive landscape report
- Placebo (WO3988) updates RSS · CI watch RSS
- Dr. August Wolff GmbH & Co. KG Arzneimittel portfolio CI